<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HALOPROGIN</span><br/>(ha-loe-proe'jin)<br/><span class="topboxtradename">Halotex<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antifungal</span><br/><b>Prototype: </b>Fluconazole<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1% cream, solution</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic iodinated phenolic ether which is fungicidal or fungistatic against certain species.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Fungicidal or fungistatic against various species of <i>Trichophyton, Epidermophyton, Microsporum, Malassezia,</i> and <i>Candida</i>. Also active in vitro against <i>Staphylococcus aureus</i> and <i>Streptococcus pyogenes</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Superficial fungal infections such as tinea pedis, tinea cruris, tinea corporis, and tinea manus. Also tinea versicolor caused
         by <i>Malassezia furfur</i>. May be used in combination antiinfective therapy for mixed infections.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults; severe cardiovascular disease; history of seizures of abnormal EEG; thyrotoxicosis; bipolar disorder. Safe use
         during pregnancy (category B) is not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Superficial Fungal Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply liberally to affected area b.i.d. for 23 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Wash skin gently and dry thoroughly before each application.</li>
<li>Avoid contact of medication with eyes.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Low incidence of systemic toxicity. <span class="typehead">Skin:</span> Local irritation, burning sensation, vesiculation, increased maceration, exacerbation of preexisting lesions, sensitization,
      pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Minimum absorption through intact skin. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Discontinue medication if signs of infection or irritation occur.</li>
<li>Reevaluate therapy if no improvement is noted after 23 wk.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue medication if condition worsens or if burning, irritation, or signs of sensitization occur, and consult physician.</li>
<li>Do not wear occlusive foot-wear with tinea pedis (athlete's foot) because it promotes drug absorption and enhances fungal
            growth.
         </li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>